Related Experiment Video
Updated: Jun 19, 2026
09:57
Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
Published on: September 20, 2024
Identification of pharmacoresistant epilepsy
1Department of Biology, Northern Illinois University, DeKalb, IL 60115, USA.
Neurologic Clinics
|October 27, 2009
Summary
Defining and identifying pharmacoresistant epilepsy is challenging due to variability. Early referral to an epilepsy center is recommended after two antiepileptic drug failures to improve seizure control and reduce risks.
Area of Science:
- Neurology
- Epilepsy Research
- Clinical Neuroscience
Background:
- Pharmacoresistant epilepsy lacks a universal definition, complicating diagnosis and treatment.
- Variability in epilepsy presentation and seizure control over time hinders prospective identification.
- Untreated or poorly controlled epilepsy carries significant risks, including cognitive/psychiatric issues and sudden death.
Purpose of the Study:
- To discuss the challenges in defining and identifying pharmacoresistant epilepsy.
- To highlight the importance of timely referral for specialized evaluation.
- To emphasize the critical need for optimizing seizure control.
Main Methods:
- Review of current literature and clinical recommendations regarding epilepsy pharmacoresistance.
- Discussion of diagnostic challenges and proposed thresholds for referral.
- Analysis of the impact of uncontrolled seizures on patient outcomes.
Main Results:
- Failure of two appropriate antiepileptic drug trials is a recommended threshold for referral.
- Prospective identification is complicated by inherent disease variability.
- Optimizing seizure control is crucial for mitigating epilepsy-related complications.
Conclusions:
- A standardized definition and identification strategy for pharmacoresistant epilepsy are needed.
- Early referral to comprehensive epilepsy centers is vital for effective management.
- Aggressive seizure control is paramount for improving quality of life and reducing mortality in epilepsy patients.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:22Epilepsy ll: Types
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...